retifanlimab   Click here for help

GtoPdb Ligand ID: 11583

Synonyms: hPD-1 mAb 7(1.2) [3] | INCMGA0012 | MGA012
Compound class: Antibody
Comment: Retifanlimab (MGA012) is a clinical stage humanized IgG4 anti-PD-1 monoclonal antibody. It was developed by MacroGenics for anti-cancer potential. Retifanlimab blocks the interation between PD-1 and its ligands PD-L1/2, and it acts as an immune checkpoint inhibitor.
Click here for help
References
1. Catenacci DV, Rosales M, Chung HC, H Yoon H, Shen L, Moehler M, Kang YK. (2020)
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Future Oncol, [Epub ahead of print]. DOI: 10.2217/fon-2020-1007 [PMID:33263418]
2. Farias JPF, Rangel da Silva MHC, J├ícome AA. (2021)
Emerging and Experimental Agents for Anal Cancer: What is New?.
J Exp Pharmacol, 13: 433-440. [PMID:33859504]
3. Shah K, Smith DH, La Motte-Mohs R, Johnson LS, Moore PA, Bonvini E, Koenig S. (2017)
Pd-1-binding molecules and methods use thereof.
Patent number: WO2017019846A1. Assignee: Macrogenics, Inc.. Priority date: 30/07/2015. Publication date: 02/02/2017.